The company might just be the right kind of business operating at the right time in history.
Investors weren't happy with the company's latest effort at capital-raising.
When valuations are high, even little things can lead to disappointment.
/Fastenal%20Co_%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)
Fastenal has underperformed the broader market over the past year, and Wall Street analysts remain skeptical about the stock’s prospects.
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.
The company was a standout in the biotech field, rising by nearly 23% over the period.
Good news from the lab and subsequent price target lifts by analysts put some zip into the company's shares.
Lucid is receiving another major injection of capital.